Stephen Liu: Can we predict risk of immune related toxicity with immunotherapy for NSCLC

Stephen Liu shared a post on X about a recent paper by Fei Xing et al. published in Clinical Lung Cancer, commenting:   .

“Can we predict risk of immune related toxicity with immunotherapy for NSCLC? Report Clinical Lung Cancer showed 15.2% rate of high-grade irAEs overall (esp respiratory and GI) with higher risk seen with mutations in MYC, TEK, FANCA, FAM123B, MET.”

“Mutations associated with high-grade irAEs in NSCLC patients receiving immunotherapies”

Authors: Margaret R. Smith, Yuezhu Wang, Caroline B. Dixon, Ralph D’Agostino Jr., Yin Liu, Jimmy Ruiz, George Oliver, Lance D Miller, Umit Topaloglu, Michael D. Chan, Michael Farris, Jing Su, Kathryn F. Mileham, Wencheng Li, Jason M. Grayson, Thomas Lycan, Fei Xing

Source: Stephen Liu/X

Stephen Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center.

As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies. His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer.

Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.